Strong margin expansion driven by new revenue streams, enhanced channel mix, and disciplined cost management Perfect Moment Ltd.

Allogene Therapeutics' Q2 2025 update highlights a streamlined ALPHA3 trial, promising ALLO-316 data, and financial discipline.

Special 250th anniversary designs offer a golden opportunity to grow the hobby and inspire the next generation of ...

Q2 2025 Earnings Call Transcript August 13, 2025 BiomX Inc. beats earnings expectations. Reported EPS is $-0.19, expectations ...

Q2 2025 Management View James V. Caruso, President and CEO, stated that Cellectar has made "significant strides across our ...

Honda and Acura have a pattern of showing multiple stages of concepts, those that we would more traditionally think of as ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Key Points EPS (GAAP) matched estimates at $(0.26), reflecting cost controls but ongoing net losses and no revenue. Positive clinical milestones achieved for BX211 (diabetic foot osteomyelitis) and ...

Published results include a complete clinical response in a 49-year-old man with metastatic testicular cancer following a single dose of AGENT-797, with sustained remission beyond two years and no ...